Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $65 to $70.
July 18, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank analyst George Farmer has maintained a Sector Outperform rating on Legend Biotech and increased the price target from $65 to $70.
The increase in price target from $65 to $70 and the maintained Sector Outperform rating by Scotiabank is a positive signal for investors, indicating confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100